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The present disclosure provides compositions for inhibiting 
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the disclosure include peptidyl ally! sulfone compositions 
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PEPTIDYLALLYL SULFONES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims benefit of and priority to U.S. Pro-
visional Patent Application No. 60/626,237 filed on Nov. 9, 
2004, and which is incorporated by reference in its entirety 
where permissible. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Aspects of the work disclosed herein were support in part 
by the National Institutes of Health Grant No. 1 ROI 
GM061964-0l. Therefore, the US government may have 
rights in the claimed subject matter. 
BACKGROUND 
1. Field of the Invention(s) 
This invention relates generally to protease inhibitors and 
applications thereof, more specifically to peptide inhibitors of 
cysteine proteases, even more specifically to ally! sulfones, 
methods of their use, and methods of their production. 
2. Related Art 
Protease inhibitors are important therapeutics in the treat-
ment of a variety of disease conditions including viral infec-
tions such as HIV infection. Proteases are enzymes that 
cleave proteins or peptides and are classified into several 
groups. For example, cysteine proteases form a group of 
enzymes involved in numerous disease states, and inhibitors 
of these enzymes can be used therapeutically for the treat-
ment of diseases involving cysteine proteases. 
Cysteine Proteases. 
Cysteine proteases employ a thiolate residue, which per-
forms a nucleophilic attack on the amide bond of the peptide 
backbone to form a tetrahedral intermediate. The intermedi-
ate collapses to release the first product and the resulting acyl 
enzyme then undergoes hydrolysis. Based on their sequence 
homology cysteine proteases are divided into several clans 
and families. Clan CA and clan CD contain the majority of 
cysteine proteases. The majority of cysteine proteases, such 
as papain, cal pains, cathepsins, and cruzain belong to the clan 
CA. According to the crystal structure of papain, clan CA 
proteases are unique for their catalytic triad formed by Cys, 
His, andAsn. The oxyanion hole is created by a preceding Gin 
residue. Clan CA enzymes are inhibited by E-64, a natural 
inhibitor of cysteine proteases, and cystatin. The substrate 
specificity of clan CA enzymes is primarily controlled by the 
S2 enzyme subsite. Clan CD enzymes are unique for their 
lack of inhibition by E-64 and their specificity for the Pl 
amino acid residue. Even though clan CD is the smallest of 
the clans, it contains some very important enzymes. Among 
them are caspases, legumains, gingipains, clostripain, and 
separase. 
2 
ing calpain I and calpain II. The terms "calpain I" and 
"calpain II" are used herein to refer to the micromolar and 
millimolar activated calpains, respectively, as described 
above. While calpains degrade a wide variety of protein sub-
strates, cytoskeletal proteins seem to be particularly suscep-
tible to attack. In some cases, the products of the proteolytic 
digestion of these proteins by calpain are distinctive and 
persistent over time. Since cytoskeletal proteins are major 
components of certain types of cells, this provides a simple 
10 method of detecting calpain activity in cells and tissues. Acti-
vation of calpains and/or accumulation of breakdown prod-
ucts of cytoskeletal elements have been observed in neural 
tissues of mammals exposed to a wide variety of neurodegen-
erative diseases and conditions. For example, these phenom-
15 ena have been observed following ischemia in gerbils and 
rats, following stroke in humans, following administration of 
the toxins kainate, trimethyltin, or colchicine in rats, and in 
human Alzheimer's disease. 
Other clan CA proteases, cruzain and rhodesain, are essen-
20 tial for the development and survival of the protozoan para-
sites Trypansoma cruzi and T. brucei, respectively. T. cruzi 
causes Chagas' disease in humans in South and Central 
America, whereas T. brucei causes sleeping sickness in 
humans in large areas of central and southern Africa. Current 
25 drug therapies are accompanied by serious side effects and 
widespread resistance. Thus, the need of new medicinal 
agents is urgent. 
Cathepsins comprise a large family of lysosomal cysteine 
proteases and are involved in the degradation of host connec-
30 tive tissues, the generation ofbioactive proteins and antigen 
processing. They have been implicated in a variety of disease 
states such as rheumatoid arthritis, muscular dystrophy, and 
tumor metastasis. The high similarity in the substrate speci-
ficity among the individual cathepsins presents a challenge in 
35 finding selective and thus effective cathepsin inhibitors. 
Cysteine Protease Inhibitors. 
To date, a structurally diverse variety of cysteine protease 
inhibitors have been identified. Palmer, (1995) J. Med. 
Chem., 3 8, 3193, incorporated herein by reference, discloses 
40 certain vinyl sulfones, which act as cysteine protease inhibi-
tors for cathepsins B, L, S, 02 and cruzain. Other classes of 
compounds, such as aldehydes, nitriles, a-ketocarbonyl com-
pounds, halomethyl ketones, diazomethyl ketones, (acyloxy) 
methyl ketones, ketomethylsulfonium salts and epoxy succi-
45 nyl compounds have also been reported to inhibit cysteine 
proteases. See Palmer, id, and references cited therein. How-
ever, most of these known inhibitors are not considered suit-
able for use as therapeutic agents in animals, especially 
humans, because they suffer from various shortcomings. 
50 These shortcomings include lack of selectivity, cytotoxicity, 
poor solubility, and overly rapid plasma clearance. Many 
irreversible cysteine protease inhibitors have been described 
in the review by Powers, Asgian, Ekici, and James (2002) 
Chemical Reviews, 102, 4639. See Powers, id, and references 
55 cited therein, all of which are incorporated herein by refer-
ence. 
Neural tissues, including brain, are known to possess a 
large variety of proteases, including at least two calcium-
stimulated proteases termed calpains. Calpains are present in 
many tissues in addition to the brain. Calpain I is activated by 60 
micromolar concentrations of calcium while calpain II is 
activated by millimolar concentrations. In the brain, calpain II 
Among the most effective inhibitors are the vinyl sulfones 
and a,~-unsaturated carbonyl derivatives. Hanzlik, (1984) J. 
Med. Chem., 27, 711 has replaced the carbonyl group of a 
good substrate with a Michael acceptor moiety, which can 
trap the enzymatic nucleophile (Ser-OH or Cys-OH) without 
altering the structural features required for enzyme recogni-
tion and binding. The fumarate derivative of the epoxy suc-
cinate E-64c, which is one of the first Michael acceptor 
inhibitors reported, extends the a,~-unsaturated carbonyl by 
an additional carbonyl for possible structural recognition and 
binding requirements within the enzyme active site. The 
is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
potentiation, synaptic plasticity, and cell death. Other Ca2+ 65 
activated cysteine proteases may exist, and the term "calpain" 
is used to refer to all Ca2 + activatedcysteineproteases, includ-
US 7,521,427 B2 
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Another aspect of the present disclosure provides a pepti-
dyl ally! sulfone composition containing a phenylalanine and 
leucine in the Pl and P2 position respectively. Peptidyl ally! 
sulfones having such a sequence inhibit cathepsins and can, 
therefore, treat cancer and muscular dystrophy. The same 
peptidyl ally! sulfones also inhibit the parasitic clan CA cys-
teine proteases cruzain and rhodesain. Since parasite devel-
opment is controlled by cruzain and rhodesain, administering 
an effective dose of the appropriate peptidyl ally! sulfone to 
fumarate derivative of E-64c (trans-HOOCCH=CH-CO-
Leu-NH(CH2)2CH(CH3)2) inhibits cathepsin B (kapp =625 
M- 1s- 1), cathepsin H, and cathepsin L (kapp=2272 M- 1s- 1 ) 
irreversibly. Both the fumarate analog of E-64c and the 
epoxide parent compound do not inhibit clan CD proteases, 
and are therefore specific for clan CA cysteine proteases. 
Caspases, legumains, gingipains and clostripain are members 
of clan CD, while papain, cathepsins, and calpains are mem-
bers of clan CA. Therefore, because of the aforementioned 
deficiencies in the art, there is a need for new compounds and 
methods for inhibiting proteases, in particular cysteine pro-
teases. 
10 
an infected mammal, including primates provides a treatment 
ofChagas' disease or sleeping sickness. 
In another aspect, a method is disclosed herein to identify 
proteolytic enzymes and a method to prevent proteolysis. 
Other compositions, methods of use of the compositions SUMMARY 
15 and methods of their manufacture and advantages of the dis-
closed compositions and methods will be or become apparent 
to one with skill in the art upon examination of the following 
detailed description. It is intended that all such additional 
compositions, methods, and advantages be included within 
this description, be within the scope of the present invention, 
Aspects of the present disclosure provide compositions for 
inhibiting proteases, methods for synthesizing the composi-
tions, and methods of using the disclosed protease inhibitors. 
The compositions described herein can inhibit proteases, for 
example cysteine proteases, either in vivo or in vitro, by 
contacting a cysteine protease with a peptidyl ally! sulfone. 
The disclosed compounds, pharmaceutically acceptable salts 
thereof, pharmaceutically acceptable derivatives thereof, pro-
drugs thereof, or combinations thereof can be used to treat 
disease or pathological conditions related to the activity of 25 
proteases associated with a specific disease or condition. 
Such treatable conditions include viral infections, stroke, 
neurodegenerative disease, and inflammatory disease, among 
others. 
20 and be protected by the accompanying claims. 
DETAILED DESCRIPTION OF THE INVENTION 
The present disclosure may be understood more readily by 
reference to the following detailed description and the 
Examples included therein. 
Before the present compounds, compositions and methods 
are disclosed and described, it is to be understood that this 
disclosure is not limited to specific synthetic methods, spe-Methods disclosed herein for treating diseases include 
administering an effective amount of a peptidyl ally! sulfone 30 cific pharmaceutical carriers, or to particular pharmaceutical 
formulations or administration regimens, as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
to a host, in particular a mamalian host, in need thereof to 
inhibit or reduce protease activity in the host, particularly 
cysteine protease activity, more particularly activity of the 
calpains, cathepsins, papain, and the parasitic proteases 
cruzain and rhodesain. One or more peptidyl ally! sulfones of 35 
the present disclosure can also be used alone or in combina-
tion with each other, other protease inhibitors, or another 
therapeutic agent including anti-viral compounds such as 
anti-viral nucleosides including nucleoside analogs. 
One aspect of the disclosure provides peptidyl ally! sulfone 40 
compositions, for example a compound or pharmaceutically 
acceptable salt or pharmaceutically acceptable derivative 
thereof according to Formula I below. In some aspects of the 
present disclosure, peptidyl ally! sulfone inhibitors are spe-
cific for cysteine proteases and do not inhibit serine proteases 45 
or aspartyl proteases. In another aspect of the present disclo-
sure, these peptidyl ally! sulfone compounds potently and 
specifically inhibit clan CA cysteine proteases. Although the 
compounds of the present disclosure are usually specific for 
cysteine proteases of clan CA, they are also inhibitors of other 50 
proteases. Exemplary differences between peptidyl ally! sul-
fones disclosed herein and other cysteine protease inhibitors 
include different mechanisms of inhibition of the cysteine 
residue and the binding modes. 
Some peptidyl ally! sulfones of the present disclosure can 55 
be constructed to selectively inhibit individual cysteine pro-
teases or groups of cysteine proteases. These peptidyl ally! 
sulfones can, for example, contain aliphatic residues in the P2 
site. Such peptidyl ally! sulfones are potent inhibitors of 
calpains. Peptidyl ally! sulfone calpain inhibitors are useful 
for the treatment of cell injury due to ischemic stroke, physi- 60 
cal damage, and hypoxia. Thus, another aspect provides a 
method of treating cell injury due to ischemic stroke, physical 
damage, and hypoxia including administering an effective 
amount ofa peptidyl ally! sulfone to a patient inneed thereof. 
Such patients can include any mammal, for example a mam- 65 
ma! exhibiting symptoms characteristic of a protease related 
pathology or disease condition. 
embodiments only and is not intended to be limiting. 
Cysteine Proteases. 
The peptidyl ally! sulfone compositions provided herein 
inhibit enzymatic cleavage of proteins or peptides, or a com-
bination thereof. Exemplary enzymes inhibited by peptidyl 
ally! sulfones include cysteine proteases, for example, 
calpains, cathepsins, cruzain and rhodesain. 
The present disclosure includes all hydrates, solvates, 
complexes and prodrugs of the compounds of this disclosure. 
The term prodrug refers to a pharmacologically inactive com-
pound that is converted to an active drug by a metabolic 
biotransformation. Prodrugs include compounds wherein an 
amino acid residue, or a polypeptide chain of two or more 
(e.g., two, three or four) amino acid residues is covalently 
joined through an amide or ester bond to a free amino, 
hydroxy or carboxylic acid group of compounds of Formula 
I. Additional types of prodrugs are also encompassed. For 
instance, free carboxyl groups can be derivatized as amides or 
alkyl esters. The amide and ester moieties may incorporate 
groups including but not limited to ether, amine and carboxy-
lic acid functionalities. Free hydroxy groups may be deriva-
tized using groups including but not limited to hemisucci-
nates, phosphate esters, dimethylaminoacetates, and 
phosphoryloxymethyloxycarbonyls, as outlined in D. 
Fleisher, R. Bong, B. H. Stewart, Advanced Drug Delivery 
Reviews (1996) 19, 115. Carbamate prodrugs of hydroxy and 
amino groups are also included, as are carbonate prodrugs 
and sulfate esters of hydroxy groups. Derivatization of 
hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl 
ethers wherein the acyl group may be an alkyl ester, option-
ally substituted with groups including but not limited to ether, 
amine and carboxylic acid functionalities, or where the acyl 
group is an amino acid ester as described above, are also 
encompassed. Prodrugs of this type are described in R. P. 
Robinson et al., J. Medicinal Chemistry (1996) 39, 10. 
US 7,521,427 B2 
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The subject disclosure also includes isotopically-labelled 
compounds, and the pharmaceutically acceptable salts 
thereof, which are identical to those recited in Formula I, but 
for the fact that one or more atoms are replaced by an atom 
having an atomic mass or mass number different from the 
atomic mass or mass number usually found in nature. 
Examples of isotopes that can be incorporated into com-
pounds of the present disclosure include isotopes of hydro-
gen, carbon, nitrogen, oxygen, phosphorous, fluorine and 
chlorine. Compounds of the present disclosure, prodrugs 
10 
thereof, and pharmaceutically acceptable salts of said com-
pounds or of said prodrugs, which contain the aforemen-
tioned isotopes and/or other isotopes of other atoms are 
within the scope herein. Certain isotopically-labelled com-
pounds of the present disclosure, for example those into 
which radioactive isotopes such as 3H and 14C are incorpo- 15 
rated, are useful in drug and/or substrate tissue distribution 
assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes 
are particularly preferred for their ease of preparation and 
detectability. Further, substitution with heavier isotopes such 
as deuterium, i.e., 2H, can afford certain therapeutic advan- 20 
tages resulting from greater metabolic stability, for example 
increased in vivo half-life or reduced dosage requirements 
and, hence, may be preferred in some circumstances. Isoto-
pically labeled compounds of Formula I of this disclosure and 
prodrugs thereof can generally be prepared by carrying out 25 
the procedures disclosed in the Schemes and/or in the 
Examples and Preparations below, by substituting a readily 
available isotopically labeled reagent for a non-isotopically 
labeled reagent. 
If a chiral center or another form of an isomeric center is 30 present in a compound of the present invention, all forms of 
such isomer or isomers, including enantiomers and diastere-
omers, are intended to be covered herein. Inventive com-
pounds containing a chiral center may be used as a racemic 
mixture or an enantiomerically enriched mixture. Alterna-
tively, the racemic mixture may be separated using well- 35 
known techniques, and an individual enantiomer may be used 
alone. An enantiomerically enriched mixture means a mix-
ture having greater than about 50% of a single enantiomer. In 
cases in which compounds have unsaturated carbon-carbon 
double bonds, both the cis (Z) and trans (E) isomers are within 40 
the scope of this invention. The compositions of the present 
disclosure can be substantially optically pure. Substantially 
optically pure means a composition having greater than 90%, 
preferably greater than 95%, most preferably greater than 
98% of a single optical isomer. 45 
It must be noted that, as used in the specification herein and 
the appended claims, the singular forms "a," "an" and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "an aromatic com-
pound" includes mixtures of aromatic compounds, reference 50 
to "a pharmaceutical carrier" includes mixtures of two or 
more such carriers, and the like. 
Nomenclature and Definitions. 
In discussing the interactions of peptides with cysteine 
proteases, we have utilized the nomenclature of Schechter 
55 
and Berger [Biochem. Biophys. Res. Commun. 27, 157-162 
(1967); incorporated herein by reference]. The individual 
amino acid residues of a substrate or inhibitor are designated 
Pl, P2, etc., and the corresponding sub sites of the enzyme are 
designated S 1, S2, etc. The scissile bond of the substrate is 
Pl-Pl'. The most important recognition subsites of cysteine 60 
proteases are Sl and S2. 
Amino acid residues and blocking groups are designated 
using standard abbreviations (see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules, incorporated herein by refer-
ence). An amino acid residue (AA) in a peptide or inhibitor 65 
structure refers to the part of the structure -NH--CHR1 -
CO-, where R1 is the side chain of the amino acid residue 
6 
AA. It will be appreciated that at least one of the amino acid 
residues of the ally! sulfones of the invention may be substi-
tuted by one of the well known non-naturally occurring amino 
acid residues. Alterations such as these may serve to increase 
the stability, bioavailability and/or inhibitory action of the 
peptides of the present disclosure. Moreover, any of the pep-
tidyl ally! sulfones described herein may, additionally, have a 
non-peptide macromolecular carrier group covalently 
attached to their amino and/or carboxy termini. Such macro-
molecular carrier groups may include, for example, lipid-
fatty acid conjugates, polyethylene glycol, or carbohydrates. 
The term MeAA describes an N-methylated amino acid, as 
for example MePhe, which is phenylalanine, where the nitro-
gen is substituted with a methyl group. 
The following figure shows two examples of a peptidyl 
ally! sulfone. A vinyl sulfone (AA-VS) (structure bottom) is 
a modified alpha-amino acid residue (structure left) where the 
amino acid carbonyl is replaced by a vinyl sulfone moiety.An 
amino acid ally! sulfone (AA-AS) (structure right) is a modi-
fied alpha-amino acid residue (structure left) where the amino 
acid carbonyl is replaced by an ally! sulfone moiety. As a 
result the alpha-carbon is sp2 hybridized. 
Acy! or Peptidyl......._ 
N 
H 
0 
Phenylalanine (Phe) 
Residue 
Acy'°'''''"'''- ? ,,-R N~S
H ~~ 
0 0 
Phenylalanine Ally! Sulfone (Phe-AS) 
Residue 
Phenylalanine Vinyl Sulfone (Phe-VS) 
Residue 
Therefore, substituting the carbonyl of a phenylalanine resi-
due with an ally! sulfone moiety converts a phenylalanine 
residue (Phe) to a phenylalanine ally! sulfone residue, which 
will be abbreviated as Phe-AS. 
The complete structures ofthreepeptidyl ally! sulfones and 
their abbreviated structures are shown in the following figure. 
US 7,521,427 B2 
Structure 
Carboxybenzoyl 
Cbz 
7 
Qoy~0~ 
0 /'-.... 
0 11-0 ~~~ ~ j 
0 
Ally! Sulfone 
AS 
0 11-0 ~ ~ j 
0 
0 11-0 ~ ~ j 
0 
Phe-AS-Ph 
There can be two structural isomers at the ally! sulfone 
double bond moiety, if the appropriate substituents are 
present, the trans isomers E and Z. The E and Z terminology 45 
applies to compounds that contain a C=C double bond with 
more than two substituents. The Cahn-Prelog-Ingold selec-
tion rules are used to assign priorities to the various substitu-
ents. If the two substituents with the highest priority are on the 
same side, the double bond is given the designation Z (from 50 
zusammen) and E (from entgegen), if they are on opposite 
sides. 
The wavy line in the above structure indicates that the 
double bond moiety could be either E, Z, or a mixture of both. 
55 
8 
Abbreviation 
Cbz-Ala-Phe-AS-Ph 
Cbz-Leu-Phe-AS-Ph 
Cbz-Val-Phe-AS-Ph 
-continued 
Qoy~0~ 
0 /'-.... 
Z-Isomer 
The term "amino," as used herein, refers to -NH2 or 
derivatives thereof formed by independent replacement of 
one or both hydrogen atoms thereon with a substituent or 
substituents independently selected from alkyl, alkanoyl, 
aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, het-
65 eroarylalkyl, and an amino protecting group. 
E-Isomer Theterm "C1 _10 acyl," as used herein, refers to aC1 _10 alkyl 
group, as defined herein, having an attached carbonyl group. 
US 7,521,427 B2 
9 
The term "C1_10 alkoxy," as used herein, refers to a C1 _10 
alkyl group, as defined herein, attached to the parent molecu-
lar group through an oxygen atom. 
The term "C1 _10 alkyl" as used herein refers to a branched 
or unbranched hydrocarbon group of carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, 
and the like, or branched or unbranched hydrocarbon groups 
of carbon atoms that either contain double or triple carbon 
bonds. 
10 
The term "pharmaceutically acceptable" means a material 
that is not biologically or otherwise harmful and/or toxic, i.e., 
the material may be administered to an individual along with 
the selected ally! sulfone without causing any harmful and/or 
toxic biological effects or interacting in a deleterious manner 
with any of the other components of the pharmaceutical com-
position in which it is contained. 
As used herein, and without limitation, the term "deriva-
tive" is used to refer to any compound that has a structure 
The term "C1 _10 alkylamino," as used herein, refers to a 
C1 _10 alkyl group, as defined herein, to which is attached at 
least one amino substituent. 
10 derived from the structure of the compounds of the present 
invention and whose structure is sufficiently similar to those 
disclosed herein and that, based upon that similarity, would be 
expected by one skilled in the art, to exhibit the same or The term "C3 _15 cycloalkyl" as applied herein is meant to 
include cyclic hydrocarbon chains. Examples of these cyclic 
hydrocarbon chains include cyclopropane, cyclobutane, 15 
cyclopentane, cyclohexane, cycloheptane, cyclooctane, 
cyclononane, cyclodecane, cycloundecane, etc. 
similar activities and utilities as the claimed compounds. 
The following abbreviations have also been used: AC, 
Acetyl; AFC, 7-amino-4-trifluoromethylcoumarin; AS, ally! 
sulfone; AMC, 7-amino-4-methylcoumarin; Boe, tert-bu-
toxycarbonyl; Brij, polyoxyethylenelaurylether; Bzl, benzyl; 
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio ]-l-pro-
The term "C2 _12 dialkylamino," as used herein, refers to 
two C1_10 alkyl groups, as defined herein, that are attached to 
an amino substituent. 
The term "C1 _10 fluoroalkyl," as used herein, refers to a 
C1 _10 alkyl group, as defined herein, to which is attached at 
least one fluorine substituent. 
The term "C1_10 perfluoroalkyl," as used herein, refers to a 
cl-10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. 
20 panesulfonate; Cbz, Ph-CH20CO-; DCC, 1,3-dicyclohexy-
lcarbodiimide; DMAP, 4-dimethylaminopyridine; DMF, 
N,N-dimethylformamide; DMSO, dimethylsulfoxide; DTT, 
dithiothreitol; EDC, 1-(3-dimethylaminopropyl)-3-ethylcar-
bodiimide hydrochloride; EtOAc, ethyl acetate; EtPh, Eth-
25 ylphenyl; HEPES, N-2-hydroxyethylpiperazine-N'-2-
The term "biotinyl," as use herein, refers to biotin without 
the biotin carboxyl hydroxyl group. 
ethanesulfonic acid; Hph, homophenylalanine; HOBt, 
1-hydroxybenzotriazole; HRMS, high resolution mass spec-
trometry; iBCF, isobutyl chloroformate; IBX, iodooxyben-
zoic acid; IC, inhibitory concentration; Mu, morpholine urea; By the term "effective amount" of a compound as provided 
herein is meant a nontoxic but sufficient amount of the com-
pound to provide the desired utility. As will be pointed out 
below, the exact amount required will vary from subject to 
subject, depending on the species, age, and general condition 
30 2-Napth or 2Np, 2-naphthyl; NMM, 4-methylmorpholine; 
Np2,2-naphthylalanyl; Ph, phenyl; PhPr, Phenylpropyl; Pyr, 
pyridine; TFA, trifluoroacetic acid; THF, tetrahydrofuran; 
TLC, thin layer chromatography; VS, vinyl sulfone. 
of the subject, the severity of the condition or disease that is 
being treated, the particular compound used, its mode of 35 
administration, and the like. Thus, it is not possible to specify 
an exact "effective amount." However, an appropriate effec-
tive amount may be determined by one of ordinary skill in the 
art using only routine experimentation. 
The term "pharmaceutically acceptable salt(s)", as used 40 
herein, unless otherwise indicated, includes salts of acidic or 
basic groups, which may be present in the compounds of 
Formula I. The compounds of Formula I that are basic in 
nature are capable of forming a wide variety of salts with 
various inorganic and organic acids. The acids that may be 45 
used to prepare pharmaceutically acceptable acid addition 
salts of such basic compounds of Formula I are those that 
form non-toxic acid addition salts, i.e., salts containing phar-
macologically acceptable anions, such as the hydrochloride, 
hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phos- 50 
phate, acid phosphate, isonicotinate, acetate, lactate, salicy-
late, citrate, acid citrate, tartrate, TFA, pantothenate, bitar-
trate, ascorbate, succinate, maleate, gentisinate, fumarate, 
gluconate, glucaronate, saccharate, formate, benzoate, 
glutamate, methanesulfonate, ethanesulfonate, benzene- 55 
sulfonate, p-toluenesulfonate and pamoate (i.e., 1, 1 '-methyl-
ene-bis-(2-hydroxy-3-naphthoate )) salts. Those compounds 
of Formula I that are acidic in nature, are capable of forming 
base salts with various pharmacologically acceptable cations. 
Examples of such salts include the alkali metal or alkaline 60 
earth metal salts and particularly, the sodium and potassium 
salts. 
The term "pharmaceutically acceptable derivative" refers 
Compositions 
One embodiment of the present disclosure provides pepti-
dyl ally! sulfones having the following structural Formula I: 
wherein, 
R1 is selected from the group including, but not limited to, 
M1 -AA1 , M1-AA2 -AAu and M1-AA3 -AA2 -AA1 ; 
M 1 is selected from the group including, but not limited to, 
H, NH2--CO-, NH2-CS-, NH2-S02-, X-NH-
CO-, X2N-CO-, X-NH-CS-, X2N--CS-, 
X-NH-S02-, X2N-S02-, X-CO-, X-CS-, X-, 
Y-S02-, Y-0---CO-, Y-0---CS-, 4-morpholine-
CO-, N-methylpiperidine-CO-, piperazine-CO-, N-me-
thylpiperazine-CO-, and biotinyl; 
X is selected from the group including, but not limited to, 
H, C1_10 alkyl, C3 _15 cyclized alkyl, C1 _10 fluoroalkyl, C1_10 
alkyl substituted with J, C1 _10 fluoroalkyl substituted with J, 
1-admantyl, 9-fluorenyl, phenyl, pentafluorophenyl, phenyl 
monosubstituted with K, phenyl disubstituted with K, phenyl 
trisubstituted with K, naphthyl, naphthyl monosubstituted 
with K, naphthyl di substituted with K, naphthyl trisubstituted to any homolog, analog, or fragment corresponding to the 
ally! sulfones of the present invention provided herein which 
inhibits protease activity and is relatively non-toxic to the 
subject or host. 
65 withK, C1 _10 fluoroalkyl with an attached phenyl group, C1_10 
alkyl with an attached phenyl group, C1_10 alkyl with two 
attached phenyl groups, cl-10 alkyl with an attached phenyl 
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group substituted with K, C1_10 alkyl with two attached phe-
nyl groups substituted with K, C1_10 alkyl with an attached 
naphthyl group, C1_10 alkyl with an attached naphthyl group 
substituted with K, C1_10 alkyl with an attached phenoxy 
group, and C1_10 alkyl with an attached phenoxy group sub-
stituted with K on the phenoxy group; 
Y is selected from the group including, but not limited to, 
cl-10 alkyl, c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl 
substituted with J, C1_10 fluoroalkyl substituted with J, 1-ad-
mantyl, 9-fluorenyl, phenyl, phenyl monosubstituted with K, 
phenyl disubstituted with K, phenyl trisubstituted with K, 
naphthyl, naphthyl monosubstituted with K, naphthyl disub-
stituted with K, naphthyl trisubstituted with K, C1_10 fluoro-
alkyl with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group, cl-10 alkyl with two attached phenyl 
groups, C1_10 alkyl with an attached phenyl group substituted 
with K, C1_10 alkyl with two attached phenyl groups substi-
tuted with K, C1_10 alkyl with an attached naphthyl group, 
C1_10 alkyl with an attached naphthyl group substituted with 
K, C1_10 alkyl with an attached phenoxy group, and C1_10 
alkyl with an attached phenoxy group substituted with Kon 
the phenoxy group; 
J is selected from the group including, but not limited to, 
halogen, C02H, OH, CN, N02, amino, C1_10 alkoxy, C1_10 
alkylamino, C2_12 dialkylamino, C1_10 alkyl-0---CO-, C1_10 
alkyl-0---CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group including, but not limited to, 
halogen, cl-10 alkyl, cl-10 perfluoroalkyl, cl-10 alkoxy, phe-
noxy, N02, CN, OH, C02H, CONH2, amino, C1_10 alky-
lamino, c2-12 dialkylamino, cl-10 acyl, and cl-10 alkoxy-
CO-, and C1_10 alkyl-S-; 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, or no 
chirality at the alpha-carbon, selected from the group consist-
ing of alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, his-
tidine, phenylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutanoic acid, epsilon-aminocaproic acid, citrul-
line, hydroxyproline, omithine, homoarginine, sarcosine, 
indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-C02H, alpha-aminohep-
tanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, NH2--CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2CH2CH2-phenyl)-
C02H, NH2--CH(CH2-cyclohexyl)-C02H, NH2--CH 
(CH2-cyclopentyl)-C02H, NH2--CH(CH2-cyclobutyl)-
C02H, NH2--CH(CH2-cyclopropyl)-C02H, 
trifluoroleucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, hexafluoroleucine, 
10 
15 
20 
25 
12 
-continued 
H2N 
C02H H2N 
C02H 
s 
H2N H2N H2N 
C02H C02H C02H 
and 
H2N H2N 
C02H C02H 
R2 is selected from the group including, but not limited to, 
cl-10 alkyl, cl-10 perfluoroalkyl, cl-10 alkyl substituted with 
30 Q, cl-10 alkyl substituted with phenyl, cl-10 alkyl with an 
attached phenyl substituted with K, C1_10 alkyl substituted 
with naphthyl, C1_10 alkyl with an attached naphthyl substi-
tuted with K, phenyl, phenyl substituted with K, naphthyl, 
naphthyl substituted with K, C1_10 alkyl substituted with 35 CONH2, C1_10 alkyl substituted with CONHR4 , C1_10 alkyl 
substituted with C02H, C1_10 alkyl substituted with S02NH2, 
C1_10 alkyl substituted with S03H, 2-furyl, 3-furyl, 2-thienyl, 
3-thienyl, 2-furyl substituted with K, 3-furyl substituted with 
K, 2-thienyl substituted with K, 3-thienyl substituted with K, 
40 2-furyl substituted with G, 3-furyl substituted with G, 2-thie-
nyl substituted with G, 3-thienyl substituted with G, C1_10 
alkyl substituted with C02R5, CH2CH2SCH3, CH2-3-in-
dolyl, cl-2 alkyl with an attached 2-furyl, cl-2 alkyl with an 
attached 3-furyl, cl-2 alkyl with an attached 2-thienyl, cl-2 
45 alkyl with an attached 3-thienyl, C1_2 alkyl with an attached 
2-furyl substituted with K, C1_2 alkyl with an attached3-furyl 
substituted with K, C1_2 alkyl with an attached 2-thienyl sub-
stituted with K, C1_2 alkyl with an attached 3-thienyl substi-
tuted with K, C1_2 alkyl with an attached 2-furyl substituted 50 with G, C1_2 alkyl withanattached3-furyl substituted with G, 
C1_2 alkyl with an attached 2-thienyl substituted with G, C1_2 
alkyl with an attached 3-thienyl substituted with G, CH2-2-
imidazyl, C1_10 alkyl substituted with G, C1_10 alkyl with an 
attached phenyl substituted with G, C1_10 alkyl with an 55 attachednaphthyl substituted with G, phenyl substituted with 
G, and naphthyl substituted with G; 
R4 is selected from the group including, but not limited to, 
cl-10 alkyl and cl-10 alkyl substituted with phenyl; 
60 Q is selected independently from the group including, but 
not limited to, C1_10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy 
substituted with phenyl, and C1_10 alkyl-S- substituted with 
phenyl; 
G is selected from the group including, but not limited to, 
65 amidino (--C( NH)NH2), guanidino (-NHC(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), amino, C1_6 alky-
lamino, c2-12 dialkylamino, and imidazyl; 
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R3 is selected independently from the group including, but 
not limited to, phenyl, phenyl monosubstituted with K, phe-
nyl disubstituted with K, phenyl trisubstituted with K, naph-
thyl, naphthyl monosubstituted with K, naphthyl disubsti-
tuted with K, naphthyl trisubstituted with K, C1_10 alkenyl, 
c3-15 cyclized alkyl, cl-10 alkyl with a phenyl group attached 
to theC1 _10 alkyl, C3 _15 cyclizedalkyl with an attached phenyl 
group, C1 _10 alkyl with an attached phenyl group monosub-
stituted with K, C1 _10 alkyl with an attached phenyl group 10 
disubstituted with K, C1_10 alkyl with an attached phenyl 
group trisubstituted with K, C3 _15 cyclized alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl with a 
naphthyl group attached to the cl-10 alkyl, c3-15 cyclized 
alkyl with an attached naphthyl group, C1 _10 alkyl with an 15 
attached naphthyl group mono substituted with K, C1 _10 alkyl 
with an attached naphthyl group disubstituted with K, C1_10 
alkyl with an attached naphthyl group trisubstituted with K, 
C3 _15 cyclized alkyl with an attached naphthyl group substi- 20 
tuted with K; 
or a pharmaceutically acceptable salt, pharmaceutically 
acceptable derivative, hydrate or solvate thereof. 
Another embodiment of the present invention includes the 
above compounds with formula I, wherein the double bond 
carbons have stereochemistry selected from the group con-
sisting of E and Z. 
The following compounds are representatives of the inven-
tion: 
Cbz-Ala-Phe-AS-Ph, 
Cbz-Val-Phe-AS-Ph, and 
Cbz-Leu-Phe-AS-Ph. 
Methods of Preparation 
1. Preparation of the Vinyl Sulfone Precursor 
30 
35 
A) Preparation of the Phenyl Sulfonyl Phosphonate Pre- 40 
cursor 
14 
W einreb-Arnide 
C) Homer-Wittig Coupling 
NMM,i-BCF 
CH2Cl2 
The Boe-protected vinyl sulfone was prepared using a 
Wittig-Horner coupling from the amino acid aldehyde and the 
phosphonate precursor. 
NaOMe 
-MeOH 
The peptide portion of the peptidyl aldehyde can be prepared 
using standard peptide chemistry which is well described in 
publications such as The Peptides, Analysis, Synthesis, Biol-
ogy, Vol. 1-9, published in 1979-1987 by Academic Press; 
Houben-Wey! Methoden der Organischen Chemie, Vol. 15, 
The phenyl sulfonyl phosphonate precursor was prepared 
by reaction of diethyl phosphonate with chloromethyl phenyl 
sulfide with subsequent oxidation. 
o-S-CH2Cl 
130° C. 
Parts 1 and 2, Synthese van Peptiden, published by Georg 
Thieme Verlag, Stuttgart in 1974; and Houben-Wey! Methods 
of Organic Chemistry, Vol. E22, Parts a, b, c, and d, Synthesis 
45 
of Peptides and Peptidomimetics published by Georg Thieme 
Verlag, Stuttgart 2000-2003 (references incorporated herein 
by reference). 
o-S-CH2PO(OCH2CH3)2 
0- KMn04 ~ j S-CH2PO(OCH2CH3)i -
0 0-11 1i-CH2PO(OCH2CH3)2 
0 
B) Preparation of the Aldehyde Precursor 
The amino acid aldehyde precursor was prepared by for-
mation of the Weinreb amide from a Boe-protected amino 
acid and N,0-dimethylhydroxylamine with subsequent 
reduction. 
The M1 group can be introduced using a number of differ-
50 ent reaction schemes. First, it could be introduced directly on 
an amino acid as shown in the following scheme (top), or the 
M1 group could be introduced by reaction with an amino acid 
ester, followed by removal of the ester group to give the same 
product (bottom). 
55 
60 
H-AA-OH Mi-AA-OH 
H-AA-OR' Mi-AA-OR' -- Mi-AA-OH 
The techniques for introduction of the M1 group are well 
documented in The Peptides, Houben-Wey!, and many other 
textbooks on organic synthesis. For example, reaction with 
cyanate orp-nitrophenyl cyanate would introduce a carbamyl 
65 group (M1=NH2CO-). Reaction with Me2NCOCI would 
introduce the Me2NCO- group. Reaction with p-nitrophe-
nyl thiocarbamate would introduce a thio carbamyl group 
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(M1=NH2CS-). Reaction with NH2 S02Cl would introduce 
the NH2 S02- group. Reaction with Me2NS02Cl would 
introduce the Me2NS02 - group. Reaction with a substituted 
alkyl or aryl isocyanate would introduce the X-NH-CO-
group, where Xis a substituted alkyl or aryl group. Reaction 5 
with a substituted alkyl or aryl isothiocyanate would intro-
duce the X-NH--CS- group, where X is a substituted 
alkyl or aryl group. Reaction with X-S02--Cl would intro-
duce the X-S02- group. Reaction with a substituted alkyl 
or aryl acid chloride would introduce an acyl group (M=X- 10 
CO-). For example, reaction withMeO--CO-CH2CH2 -
CO--Cl would give the X-CO- group, where X is a C2 
alkyl substituted with a C1 alkyl-OCO- group. Reaction 
with a substituted alkyl or aryl thioacid chloride would intro-
duce a thioacyl group (M=X--CS-). Reaction with a sub- 15 
stituted alkyl or aryl sulfonyl chloride would introduce the 
X-S02-group. For example, reaction with dansyl chloride 
would give the X-S02- derivative, where X was a naphthyl 
group mono substituted with a dimethylamino group. Reac-
tion with a substituted alkyl or aryl chloroformate would 20 
introduce the X-0---CO- group. Reaction with a substi-
tuted alkyl or aryl chlorothioformate would introduce the 
X-0---CS- group. There are many alternate reaction 
schemes which could be used to introduce all of the above M 1 
groups to give either M1 -AA-OH or M 1 -AA-OR'. 25 
The M1 -AA-OH derivatives could then be used directly in 
the preparation of peptidyl vinyl sulfones or could be con-
verted into the dipeptides, tripeptides, and tetrapeptides 
M1 -AA-AA-OH, M1 -AA-AA-AA-OH, or M1 -AA-AA-AA-
AA-OH, which could then be converted to peptidyl ally! 30 
sulfones. The substituted peptides M1 -AA-AA-OH, M1 -AA-
AA-AA-OH, or M1 -AA-AA-AA-AA-OH could also be pre-
pared directly from H-AA-AA-OH, H-AA-AA-AA-OH, or 
H-AA-AA-AA-AA-OH using the reactions described above 
for introduction of the M1 group. Alternatively, the M1 group 35 
could be introduced by reaction with carboxyl blocked pep-
tides to give M1 -AA-AA-OR', M 1-AA-AA-AA-OR', or 
M1 -AA-AA-AA-AA-OR', followed by the removal of the 
blocking group R'. 
16 
Peptides were synthesized using standard coupling proce-
dures such as the mixed anhydride method. The 1 H NMR 
spectra were obtained using a Varian Mercury 400 MHz spec-
trometer. Electrospray ionization (ESI), fast-atom-bombard-
ment (FAB) and high-resolution mass spectrometry were per-
formed using Micromass Quattro LC and VG Analytical 
70-SE instruments. Elemental analysis was performed by 
Atlantic Microlab Inc., Norcross, Ga. 
B) Preparation of Peptidyl Vinyl and Ally! Sulfones 
Exemplary proceedures for preparation of the compounds 
and compositions of the present disclosure, and precursors 
thereof, are set forth below. 
General Procedure for the Mixed Anhydride Coupling. 
N-Methylmorpholine was added to Boe-AA-OH or Cbz-
AA-OH in CH2Cl2 at -lS° C. followed by isobutyl chloro-
formate. N-Methylmorpholine was added to a cooled solution 
(-lS° C.) ofHCl.H-AA-VS-PhinCH2 Cl2 . This solution was 
added to the Boc-AA-0 H or Cbz-AA-0 H mixture, which had 
been stirring at - l S° C. The mixture was continued to stir at 
- l S 0 C. for 30 minutes, then warmed to room temperature and 
continued to stir over night. The amount of solvent was 
doubled, then washed with citric acid (10%, 3x), saturated 
NaHC03 (3x), andbrine(3x), andfinallydried(MgS04 ). The 
solvent was evaporated. 
Diethy I Pheny lsulfony lmethanephosphonate 
(PhS02CH2 PO(OEt)2 ). 
A mixture of chloromethyl phenyl sulfide (3.2 g, 20 
mmole) and triethyl phosphite (3.3 g, 20 mmole) was heated 
at 130-140° C. for Sh. The resultant mixture was distilled 
under reduced pressure, and the starting materials were dis-
tilled out. The oily residue was diethyl phenylmercaptom-
ethanephosphonate, yield 3.4 g (6S%). 1H-NMR (CDCl3 ) ll 
1.2-1.3 (t, 6H, 2xCH3 ), 3.1-3.2 (d, 2H, S-CH2 ), 4.0-4.2 (m, 
4H, 2xCH2 ), 7.2-7.4 (m, SH, Ph). Diethyl phenylsulfonyl-
methanephosphonate was prepared by oxidation of diethyl 
phenylmercaptomethanephosphonate with potassium per-
manganate, yield SS%. 1H-NMR (CDCl3 ) ll 1.2-1.3 (t, 6H, 
2xCH3 ), 3.7-3.8 (d, 2H, S02--CH2 ), 4.1-4.2 (m, 4H, 
2xCH2 ), 7.S-7.7 (m, 3H, Ph), 7.9-8.0 (d, 2H, Ph). MSm/z293 
2. Preparation of the Peptidyl Ally! Sulfones 
40 (M+l). 
The peptidyl vinyl sulfone precursors were converted into 
peptidyl ally! sulfones using strong basic conditions. The 
reaction times can be reduced by adding a peroxidizing agent. 
An exemplary reaction is shown below. 
Peptidyl or Acyl'-
N 
H 
0 11-0 ~ \ ;) 
0 
0 
t-BuLi 
2-( tert-Butoxycarbonylamino )-3-phenylpropionaldehyde 
(Boc-Phe-H). 
Boc-Phe-N(OCH3 )CH3 was prepared from Boc-Phe-OH 
and N,0-dimethylhydroxylamine hydrochloride using stan-
45 dard mixed anhydride coupling procedure, yield 93%. 
1H-NMR (CDCl3 ) ll 1.4 (s, 9H, Boe), 2.8-2.9 (m, lH, CH2 -
Phe), 3.0-3.1 (m, lH, CH2 -Phe), 3.2 (s, 3H, N--CH3 ), 3.6 (s, 
3H, O--CH3 ), 4.9 (m, lH, a-H), S.2 (b, lH, NH), 7.1-7.3 (m, 
SH, Ph). MS (FAW) m/z 309 (M+l, 30%), 2S3 (M-tBu+l, 
50 100%). Reduction of Boc-Phe-N(OCH3)CH3 with lithium 
aluminum hydride according to a previous method described 
in J. A. Fehrentz et al., Synthesis (1983), 8, 676 gave Boc-
Phe-H, yield 88%. 1H-NMR (CDCl3 ) ll 1.4 (s, 9H, Boe), 3.1 
(d, 2H, CH2 -Phe), 4.4 (m, lH, a-H), S.O (b, lH, NH), 7.1-7.3 
55 (m, SH, Ph), 9.6 (s, lH, CHO). MS (FAB+) m/z 2SO (M+l, 
1S%), lSO (M-Boc+l, 100%). 
Phenyl-(3S)-3-amino-4-phenylbut-l-enyl Sulfone Hydro-
Peptidyl or Acyl'-
N 
H 
11-0 ~ \ ;) 60 chloride (Phe-VS-Ph.HCI). Boc-Phe-VS-Ph was prepared by reaction ofBoc-Phe-H with diethyl phenylsulfonylmethane-phosphonate in the presence of 2 N sodium methoxide, yield 
8S%. 1H-NMR (CDCl3 ) ll 1.3-1.4 (s, 9H, Boe), 2.9 (d, 2H, 
3. Synthetic Procedures and Examples 
A) Material and Methods 
0 
Boe and Z-protected amino acid precursors were pur-
chased from Bachem Bioscience Inc., King of Prussia, Pa. 
CH2 -Phe), 4.4-4.S (b, lH, a-H), 4.6-4.7 (b, lH, NH), 6.3 (d, 
lH, CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.3 (m, SH, Ph), 
7.S-7.8 (m, SH, S02 -Ph). MS (FAB+) m/z 388 (M+l, 1S%), 
65 288 (M-Boc+l, 100%). Boc-Phe-VS-Ph was deblocked with 
6.7 N HCI in EtOAc to give Phe-VS-Ph.HCI, yield 88%. 
1H-NMR (DMSO-d6 ) ll 2.9-3.0 (m, lH, CH2 -Phe), 3.1-3.2 
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(m, lH, CH2 -Phe), 4.2 (b, lH, a-H), 6.7-6.8 (m, 2H, CH=), 
7.1-7.3 (m, 6H, CH= and Ph), 7.6-7.8 (m, SH, S02 -Ph), 
8.6-8.8 (b, 2H, NH2). MS (FAB+) m/z 288 (M-Cl, 100%). 
D-Phe-VS-Ph.HCI, white solid, 8S% yield 
Phenyl-(3 S)-3-(N-carbobenzy loxyleucy l)amino-4-phe-
ny lbut- l -eny l Sulfone (Cbz-Leu-Phe-VS-Ph). 
18 
resorption. These structures may be used in vivo to treat 
parasitic infections such as sleeping sickness or Chagas' dis-
ease. 
1. Enzyme Assays. 
Papain and Cathepsin B Assays. 
The incubation method was used to measure the irrevers-
ible inhibition of papain and cathepsin B. With cathepsin B, 
30 µL of a stock inhibitor solution was added to 300 µL of a 
0.1 M potassium phosphate buffer containing l.2S mM 
Cbz-Leu-Phe-VS-Ph was prepared from Cbz-Leu-OH and 
Phe-VS-Ph.HCI using standard mixed anhydride coupling 
method, yield 82%. 1H-NMR (CDCl3) ll 0.8-0.9 (2d, 6H, 
2xLeu-CH3), 1.4-1.6 (m, 2H, Leu-CH2 ), 2.06 (m, lH, Leu-
CH), 2.9-3.0 (m, 2H, CH2 -Phe), 3.9-4.0 (m, lH, a-H), 4.8-4.9 
(b, lH, NH), 4.9-S.O (m, lH, a-H), S.l (m, 2H, Cbz) 6.3-6.4 
(d & b, 2H, NH and CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.4 
(m, lOH, 2xPh), 7.S-7.7 (m, SH, S02 -Ph). MS (ESI)m/z S3S. 
10 EDTA, 0.01 % Brij 3S at pH 6.0, followed by the addition of 
30 µL of a freshly prepared cathepsin B solution (approxi-
mate concentration 6.98x10-3 µg/µL) in the same potassium 
phosphate buffer containing 1 mM DTT (freshly prepared). 
Aliquots (SO µL) from the inhibition mixture were withdrawn 
Cbz-Ala-Phe-VS-Ph, white solid, 88% yield. 
Cbz-Val-Phe-VS-Ph, white solid, 98% yield. 
Cbz-Leu-D-Phe-VS-Ph, white solid, 81 % yield. 
Phenyl-3-(N-carbobenzyloxyleucyl)amino-4-phenylbut-2-
enyl Sulfone (Cbz-Leu-Phe-AS-Ph) 
15 at various time intervals and added to 200 µL of a 0.1 M 
potassium phosphate buffer containing 1.2S mM EDTA, 
0.01 % Brij 3S at pH 6.0, and the substrate Cbz-Arg-Arg-
AMC (499 µM). The release of7-amino-4-methylcoumarin 
was monitored O'-ex =360 nm, "-em =46S nm) using a Tecan 
Butyllithium (3.63 ml, 6.17 mmol, 1.7 Min pentane) was 
addeddropwiseto a solutionoftert-butylhydroperoxide (2.SS 
ml, 8.42 mmol, 3.3 Min toluene) in freshly distilled THF (80 
ml) at -78° C. under argon. A solution ofCbz-Leu-Phe-VS-
20 Spectra Fluor microplate reader. Pseudo first-order inactiva-
tion rate constants were obtained from plots ofln v /v 0 versus 
time. 
The incubation method was also used for commercially 
available papain. The inhibition incubation buffer for papain 
25 was SO mM Hepes buffer at pH 7 .S, containing 2.S mM DTT 
(dithiothreitol) and 2.S mM EDTA. The assay used the sub-
strate Cbz-Phe-Arg-pNA (S3.7 µM) in the same buffer. The 
approximate concentration of papain added to the incubation 
buffer was 0.29 mg/mL. The release of p-nitroanilide was 
Ph (3.00 g, S.61 mmol) in dry THF (30 ml) was added drop-
wise. The reaction was continued to stir at -20° C. for 4S 
minutes (TLC Hex/EtOAc 1: 1 ). The reaction was quenched 
with saturated aqueous ammonium chloride (SO ml) and 
allowed to warm to room temperature. The organic layer was 
separated, and the aqueous layer was extracted with ethyl 
acetate (3x30 ml). The extracts were then washed with aque-
ous sodium sulfite (10%, 3x20 ml). The combined organic 
layers were dried (MgS04) and evaporated to give Cbz-Leu-
Phe-AS-Ph as a white powder, yield 63%. 1H-NMR (CDCl3) 35 
ll 0.8-0.9 (2d, 6H, 2xLeu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 
3.8 (s, 2H, CH2 -Phe), 3.9 (d, 2H, CH2-S02 ), 4.1 (m, lH, 
a-H), 4.8 (t, lH, CH=), 4.9-S.O (b, lH, NH), S.l (m, 2H, 
Cbz), 7.1-7.4 (m, lOH, 2xPh), 7.S-7.7 (m, SH, S02 -Ph), 8.4 
30 monitored at 40S nm with a Molecular Devices Thermomax 
(b, lH, NH). 13C NMR (400 MHz, CDCl3) ll 172.1, 1S6.3, 40 
144.4, 140.8, 13S.7, 134.2, 133.6, 131.2, 129.S, 129.4x2, 
129.3, 128.8x2, 128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 
126.9, 106.3, 67.6, S6.0, SS.6, 41.7, 40.4, 22.1, 21.0, 18.4. MS 
(FAB+) m/z S3S (M+l, 100%). Anal. Calcd. for 
C30H34N2 0 5S: C, 67.39; H, 6.S6; N, S.43. Found: C, 67.41; 45 
H, 6.S6; N, S.43. 
Cbz-Leu-Phe-AS-Ph (derived from Cbz-Leu-D-Phe-VS-
Ph) white solid, 1 S% yield. 
microplate reader. All assays were run in duplicate. 
Calpain Assays. 
Calpain I was purchased from Calbiochem (La Jolla, 
Calif.) in a solution of30% glycerol at a concentration of 6.96 
µMand stored at -20° C. prior to use. The calpainl assay was 
conducted with 23S µL of a solution of SO mM Hepes, O.S M 
CaCl2 , O.S M cysteine, at pH 7 .S ( calpain I buffer), 6.S µL of 
Suc-Leu-Tyr-AMC substrate solutioninDMSO and4.2 µL of 
the enzyme solution (6.96 µM) at 23° C. The enzymatic 
activity was monitored by following the change in fluores-
cence for 10 min at 46S nm. The k2 values were obtained by 
non-linear regression analysis and corrected for substrate 
(l+[S]/KM=l.274). All assays were run in duplicate and the 
standard deviation was determined. 
Cathepsin L Assays. 
Cathepsin L was purchased from Athens Research & Tech-
nology (Athens, Ga.) in a 20 mM malonate buffer solution at 
pH S.S with 1 mM EDTA and 400 mM NaCl with a specific 
activity of 4.133 U/mg. The progress of cathepsinL inhibition Cbz-Val-Phe-AS-Ph white solid, 21 % yield. 
Cbz-Ala-Phe-AS-Ph, white solid, 93% yield. 
Methods of Use of Compounds of the Present 
Disclosure 
50 was conducted with 243 µL of a solution of 0.2S M NaAc, 2 
mM EDTA, O.OlS% Brij, S mM DTT (dithiothreitol) at pH 
S.S, 4 µL ofCbz-Phe-Arg-AMC substrate solution (16 mM) 
in DMSO (2% final concentration). Activity was monitored 
by following the change in fluorescence for 20 min at 46S nm. 
Peptide ally! sulfones are irreversible inhibitors for cys-
teine proteases. We show that peptide ally! sulfones contain-
ing aliphatic side chains in the P2 site are excellent inhibitors 
of clan CA cysteine proteases. These structures may be used 
55 Thek06s values were obtained by non-linear regression analy-
sis and corrected for substrate (l+[S]/KM=l .274). All assays 
were run in duplicate and the standard deviation was deter-
mined. 
in vivo to treat diseases such as cancer and neurodegenerative 
diseases, which result from the uncontrolled proteolysis by 60 
cathepsins and calpains, and related cysteine proteases. These 
inhibitors may be used in vitro to prevent proteolysis, which 
occurs in the process of production, isolation, purification, 
storage, or transport of peptides and proteins. These inhibi-
tors may be useful as therapeutic agents for treatment of 65 
neurodegeneration, viral infections, muscular dystrophy, 
myocardial tissue damage, tumor metastasis, and bone 
Cruzain and Rhodesain IC50 Determinations. 
Inhibitors were screened for effectiveness against purified 
recombinant cruzain and rhodesain. Cruzain (2 nM) or rhode-
sain (3 nM) was incubated with 0.0001 to 1 µM inhibitor in 
100 mM sodium acetate buffer, pH S.S and S mM DTT (buffer 
A), for S minutes at room temperature. Buffer A containing 
Cbz-Phe-Arg-AMC (Bachem, KM=l µM,AMC=7-amino-4-
methylcoumarin) was added to the enzyme and inhibitor to 
give 20 or 10 µM substrate concentration for cruzain and 
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rhodesain, respectively, in 200 µL. The increase in fluores-
cence (excitation at 355 run and emission at 460 run) was 
followed with an automated microtiter plate spectrofluorim-
eter (Molecular Devices, Flex Station). Inhibitor stock solu-
tions were prepared at 20 mM in DMSO and serial dilutions 
were made in DMSO (0.7% DMSO in assay). Controls were 
performed using enzyme alone, and enzyme with DMSO. 
IC50 values were determined graphically using inhibitor con-
centrations in the linear portion of a plot of enzyme activity 
versus log [I] (7 concentrations tested with at least 2 in the 
linear range). 
Table 1 shows the inhibitory constants (k06)[I] or IC50) for 
the inhibition of calpain I, papain, cathepsin B and L, cruzain 
and rhodesain. The inhibition constants k06/[I] are pseudo-
first order rate constants and the inhibitors with the higher 
numbers are more potent. The inhibition constants IC50 rep-
resent the inhibitory concentration at which the inhibitor 
inactivates 50% of the enzyme. The lower the IC50 the more 
potent is the inhibitor. 
TABLE 1 
Inhibition of Clan CA Proteases by Peptidyl Ally! Sulfones. 
20 
ally! double bond. There are several factors, which can con-
tribute to a mixed ratio of isomers, such as the so-called 
"syn-effect" and the chelating lithium metal. This explains 
the difference in inhibitor potency between Cbz-Leu-Phe-
AS-Ph (Isomer A), which is derived from the vinyl sulfone 
precursor Cbz-Leu-L-Phe-VS-Ph, and Cbz-Leu-Phe-AS-Ph 
(Isomer B). The initial stereochemistry of the phenylalanine 
side chain probably plays a significant role in the final ratio of 
Z to E isomers in the ally! sulfone inhibitor. The difference in 
10 potency of the two isomers is also observed with inhibition of 
cruzain and rhodesain. However, in this case the ranking is 
reversed. The Cbz-Leu-Phe-AS-Ph (Isomer A), which is 
derived from the viny I sulfone precursor Cbz-Leu-L-Phe-VS-
Ph, is more potent (I C50 =O .06 µM for cruzain and 0 .04 µM for 
15 rhodesain) than isomer B (IC50=0.3 µM for cruzain and 0.18 
µM for rhodesain). 
The novel ally! sulfone inhibitors Cbz-Leu-Phe-AS-Ph 
(both isomers) are more potent than the corresponding vinyl 
sulfone Cbz-Leu-Phe-VS-Ph; thus, these ally! sulfone inhibi-
k ,L[I] (M-1 s-1r IC 50 (uMl 
Inhibitor Calpain Ic Papaind Cathepsin Be Cathepsin Le Cruzain Rhodesain 
Cbz-Ala- 3±0 9±0 N.I! 183 ± lOg >10 >10 
Phe-AS-Ph 
Cbz-Val-Phe- 3±0 6 ± 1 N.I. 310 ±52g 
AS-Ph 
Cbz-Leu- 23 ±4 49 ± 6 N.I. 700 ± 43g 0.06 0.04 
Phe-AS-Ph 
(Isomer A)h 
Cbz-Leu- 564 ± 32g 15 ± 1 N.I. 1060 ± 12F 0.3 0.18 
Phe-AS-Ph 
(Isomer Bf 
Cbz-Leu- 550 ± 2g 10 ± 0 N.I. 219 ± 96g 2 0.5 
Phe-VS-Ph 
akobs is the pseudo first order rate constant obtained from plots of ln v /v0 vs time Wlless 
indicated otherwise. 
bCruzain (2 nM) or rhodesain (3 nM) was incubated with 0.0001 to 1 µM inhibitor in 100 
mM sodium acetate buffer, pH 5.5 and 5 mM DTT (buffer A), for 5 minutes at room tem-
perature prior to substrate addition. 
ccalpain I assay conditions: Irreversible kinetic assays were performed by the incubation 
method with calpain I from porcine erythrocytes. Enzymatic activities of calpain I were 
measured at 23° C. in 50 mM Hepes buffer (pH 7.5) containing 10 mM cysteine and 5 mM 
CaC12 . 
dPapain assay conditions: Incubation kinetics were measured using an enzyme stock solu-
tion for the papain assays, which was freshly prepared from 330 µL of enzyme storage solu-
tion (1.19 mg/mL) diluted with 645 µL papain buffer (50 mM Hepes, and 2.5 mM EDTA at 
pH 7.5) and 25 µL ofDTT (0.1 M). 
ecathepsin Band L assay conditions: Enzymatic activities of cathepsin B were measured by 
the incubation method in 0.1 M KHP04 , 1.25 mM EDTA, 0.01 % Brij, pH 6.0 buffer and at 
23° C. 
JN.I. ~no inhibition after 20 minutes of incubation. 
gkobs is obtained by the progress curve method and corrected for substrate. 
h Ally! sulfone is derived from the L-isomer of phenylalanine. 
1 Ally! sulfone is derived from the D-isomer of phenylalanine. 
Peptidyl ally! sulfones show moderate inactivation rates 
with calpain and papain, and faster rates of inactivation with 
rhodesain and cruzain. The dipeptidyl ally! sulfones do not 
inhibit cathepsin B and show limited rates with both calpain I 
and papain. In contrast are the striking second order inhibition 
rate constant (k06)[I]) values of564 M- 1s- 1 and1062 M- 1s- 1 
55 tors will likely be more effective inhibitors for treating vari-
ous disorders. Ally! sulfone inhibitors of the present disclo-
sure provide effective inhibitors of cystine proteases, in 
particular clan CA cystine proteases, such as cruzain and 
60 rhodesain. The effectiveness of the ally! sulfone inhibitors of 
the present disclosure may be further increased by modifica-
tions to the peptide sequence and the P' sulfonyl substituent. for Cbz-Leu-Phe-AS-Ph (Isomer B) with cal pain I and cathe-
psin L, respectively. This dipeptidyl ally! sulfone was synthe-
sized from the dipeptidyl vinyl sulfone precursor Cbz-Leu-
D-Phe-VS-Ph. When the double bond isomerizes, the 65 
original Z stereochemistry of the vinyl sulfone is lost and the 
product has an unknown ratio of E to Z isomers at the new 
Mechanism of Inhibition. 
One mechanism for the inhibition reaction could involve 
re-isomerisation of the peptidyl ally! sulfone to the vinyl 
sulfone. This isomerization could be catalyzed by the active 
site histidine and would be reflected by a higher inhibition 
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rate (k06/[I]) for the parent vinyl sulfone inhibitor. However, 
as the parent vinyl sulfone Cbz-Leu-Phe-VS-Ph was less 
potent with pa pain (k06)[I] = 10 M- 1 s- 1) than the correspond-
ing ally! sulfone Cbz-Leu-Phe-AS-Ph (Isomer A) (k06)[I]= 
22 
protease. Once a good inhibitor structure for a particular 
enzyme is found, it is then possible to change other charac-
teristics such as solubility or hydrophobicity by adding sub-
stituents to the M 1 or R1 , R2 , R3 , and R4 groups. 
49 M- 1s- 1 ) it is believed that the mechanism of inhibition 
does not involve re-isomerisation of the ally! sulfone to the 
vinyl sulfone with a subsequent attack of the cysteine thiol on 
the Michael acceptor double bond. This was even more pro-
nounced with cruzain and rhodesain, where the same vinyl 
sulfone was over 30 fold and 12 fold less potent with cruzain 10 
(IC50=2 µM) andrhodesain (IC50=0.5 µM), respectively, than 
the corresponding ally! sulfone Cbz-Leu-Phe-AS-Ph. With 
calpain I it is possible that the isomerization mechanism is 
occurring, since the vinyl sulfone is aneffective inhibitor of 
cal pain. 15 
The following structures are exemplary peptidyl ally! sul-
fone inhibitors for the listed enzymes. The inhibitor 
sequences were derived from peptide substrate and/or inhibi-
tor sequences in the protease literature. 
Ac-Leu-Leu-Met(02 )-AS-Ph 
Cbz-Leu-Leu-Hph-AS-Ph 
Ac-Leu-Leu-Met-AS-Ph 
Mu-Phe-Lys-AS-Ph 
Mu-2Np-Hph-AS-EtPh 
Mu-Np2-Hph-AS-2Np 
Cbz-Phe-Hph-AS-Ph 
Cbz-Leu-Leu-Leu-AS-EtPh 
Cbz-Leu-Leu-Leu-AS-Ph 
Ala-Hph-AS-Ph 
Lys(biotinyl)-Hph-AS-Ph 
4-Morpholine-CO-Phe-Hph-AS-Ph 
Cbz-Phe-Hph-AS-CHr Ph 
N-Methylpiperidine-CO-Leu-Hph-AS-Ph 
N-Methylpiperazine-CO-Leu-Hph-AS-Ph 
Piperazine-CO-Leu-Hph-AS-Ph 
for calpain I and II 
for calpain I and II 
for cruzain 
for cathepsin S 
for cathepsin L 
for cathepsin B 
for rhodesain 
forpapain 
Two other mechanisms can be envisaged for enzyme inhi-
bition by ally! sulfones (Scheme below). The active site cys-
teine could directly displace phenyl sulfinic acid in an SN2 
reaction (pathway b) or could attack the allylic double bond 
with loss of phenyl sulfinic acid (pathway a). Both pathways 20 
result in alkylation of the active site cysteine residue. It has 
previously been reported that ally! sulfones, when reacted 
with nucleophiles, undergo a tosyl elimination or displace-
ment process, in which the ally! sulfone moiety undergoes 
alkylation at either the a- or y-carbon. An alternative possi- 25 
bility for enzyme inactivation follows a mechanism-based 
pathway, which is initiated by removal of the amide nitrogen 
proton by a base or the active site histidine, followed by the 
elimination of phenyl sulfinic acid and the formation of the 
imine (Structure bottom left). The active site cysteine then 30 
reacts with the imine in a Michael addition, which also irre-
versibly alkylates the enzyme. 
2. In Vitro Uses. 
for calpain 
for DPPI (cathepsin C) 
for DPPI (cathepsin C) 
cruzain 
cruzain 
cathepsin V 
cathepsin V 
cathepsin K 
To use the above inhibitors in vitro, they are dissolved in an 
organic solvent such as dimethylsulfoxide or ethanol, and are 
added to an aqueous solution containing serine and/or cys-
teine proteases. The final concentration of the organic solvent 
should be less than 25%. The inhibitors may also be added as 
solids or in suspension. The cysteine protease inhibitors of 
this invention would be useful in a variety of experimental 
procedures where proteolysis is a significant problem. Inclu-
Elimination i 
a 
Enz 
I 
Cys 
I 
c~-d 
\ 
Cbz-Adl/~ ~ 
- s 
I 
- Cys 
-s-Cys-Enz ~ ;, I 
~ II Enz 
The peptide ally! sulfone derivatives, as shown above, bind 
to the enzymes using many of the interactions that are found 
in complexes of a particular enzyme with its substrates and/or 
inhibitors. Additional interactions with the enzyme can be 
obtained by tailoring the R3 group of the inhibitor to imitate 
the amino acid residues, which are preferred by an individual 
protease at the S140 and S2' subsites. For example, peptidyl 
ally! sulfones with R3 phenylalkyl groups would interact 
effectively with cruzain, which is shown to prefer such struc-
tures in vinyl sulfone peptide inhibitors. Likewise, the M 1 
group can interact with the S sub sites of the target cysteine 
35 sion of these inhibitors in radioimmunoassay experiments 
would result in higher sensitivity. The use of these inhibitors 
in plasma fractionation procedures would result in higher 
yields of valuable plasma proteins and would make purifica-
tion of the proteins easier. The inhibitors disclosed here could 
40 be used in cloning experiments utilizing bacterial cultures, 
yeast, and human cells to produce a purified cloned product in 
higher yield. 
The novel compounds of this disclosure are effective in the 
prevention of unnecessary proteolysis caused by cysteine 
45 proteases in the process of purification, transport and storage 
of peptides and proteins as shown, for example, in Table 1 by 
effective inhibition of many cysteine proteases. 
Diagnostic Reagents 
Peptidy I ally I sulfones of the present disclosure can be used 
50 for the identification of proteases, for example novel cysteine 
proteases. One embodiment provides a method for screening 
a sample for the presence of a protease, particularly a cysteine 
protease, by contacting the sample with a peptidyl ally! sul-
fone, for example a peptidyl ally! sulfone of Formula I, and 
55 detecting the presence of the peptidyl ally! sulfone-protease 
conjugate. Detection of the conjugate may be accomplished 
using known techniques. For example, peptidyl ally! sulfones 
of the present invention can be modified with a detectable 
label including but not limited to a radioisotope, fluorescent 
60 marker, biotin, antibody, enzyme conjugate such as horserad-
ish peroxidase, or the like. The peptidyl ally! sulfone conju-
gates can be fixed to a support, for example using known 
chemical fixatives, and a sample can then by added to the 
peptidyl ally! sulfone. Such support can be microarrays or the 
65 like. The fixed peptidyl ally! sulfone can then irreversibly or 
reversibly bind a protease, for example a cysteine protease, in 
the sample. The support can be washed to remove excess 
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sample. The peptidyl ally! sulfone-protease conjugate can 
then be eluted from the support and the protease can be 
detected or identified using conventional techniques. The 
support can be any durable substance including but not lim-
ited to metal, plastic, glass, quartz or the like. The peptidyl 
ally! sulfone can be linked to the support with a linker, for 
example a cleavable linker to facilliate the removal of pepti-
dyl ally! sulfone-protease conjugates. 
3. In Vivo Uses. 
24 
gms per patient per day). The amount ofactive ingredient that 
may be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of the peptidyl ally! 
sulfones or their pharmaceutically acceptable salts will nor-
mally be in the dosage range from 0.2 to 140 mg/kg of body 
weight. Administration is generally made by intravenous, 
intramuscular, or subcutaneous injection. Accordingly, phar-
Effective inhibitors of the proteolytic function of clan CA 
enzymes (Table 1) can be used to treat a variety of diseases. 
Cathepsins are involved in a variety of disease states, includ-
ing progressive cartilage and bone degradation associated 
with arthritis. Inhibitors of these cathepsins have reduced 
inflammation and prevented joint destruction in animal mod-
els of arthritis. Thus, effective inhibitors of cathepsins can be 
used for the treatment of arthritis. Cathepsins B and L have 
been linked to metastasis and invasion by cancer cells. Pep-
tidyl ally! sulfones, which inhibit cathepsin B and L, can 
therefore be used as thereapeutic agents for cancer. 
10 maceutical compositions for parenteral administration will 
contain from about 10 mg to 7 gms of the compounds per 
dose. In addition to the active ingredient, these pharmaceuti-
cal compositions may also contain a buffer, e.g. a phosphate 
buffer, which keeps the pH in the range from about 3.5 to 7, 
15 and a compound such as sodium chloride, mannitol, or sor-
bitol for adjusting the isotonic pressure. 
A composition for topical application can be formulated as 
an aqueous solution, lotion, jelly or an oily solution or sus-
pension. A composition in the form of an aqueous solution is 
Infection of mammals and man by the protozoan parasite 
Trypanosoma cruzi results in Chagas' disease, which causes 
heart disease. One target for treatment that has received sig-
nificant attention is cruzain, the major cysteine protease 
found in T. cruzi. Peptidyl ally! sulfones are potent inhibitors 
of cruzain and can therefore effectively treat Chagas' disease. 
20 obtained by dissolving the compounds of this invention in 
aqueous buffer solution of about pH 4 to 6.5 and, if desired, 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds of this 
invention in an oil, optionally with the addition of a swelling 
25 agent such as aluminium stearate and/or a surfactant. 
Rhodesain is a cysteine protease vital for the development EXAMPLES 
of the parasite Trypanosoma brucei rhodensiense, which 
upon infection causes sleeping sickness in humans and cattle. 
Inhibitors for the cysteine protease rhodesain can thus prevent 
parasite development and treat and/or prevent sleeping sick-
ness. 
The following detailed examples are given to illustrate the 
30 
present disclosure and are not intended to limit it in any 
Calpains have been implicated in a variety of physiological 
disorders, such as neurodegeneration in Alzheimer's, Parkin-
son's, and Huntington's disease, spinal injury and muscular 35 
dystrophy and other neurodegenerative disorders, including, 
but not limited to, stroke, multiple scelrosis, neurophathies, 
dentatorubropallidoluysian astrophy, spinocerebellar atro-
phy type 3, spinal bulbar muscular atrophy, peripheral neur-
opathy, and myotrophic lateral sclerosis. Other diseases 40 
include cardiac ischemia, cataract formation, thromolytic 
platelet aggregation, restenosis, joint inflammation and 
arthritis. The ability of peptidyl ally! sulfones to inhibit 
manner. 
Example 1 
Diethy I Pheny lsulfony lmethanephosphonate 
(PhS02CH2 PO(OEt)2). A mixture of chloromethyl phenyl 
sulfide (3.2 g, 20 mmole) and triethyl phosphite (3.3 g, 20 
mmole) was heated at 130-140° C. for 5 h. The resultant 
mixture was distilled under reduced pressure, and the starting 
materials were distilled out. The oily residue was diethyl 
phenylmercaptomethanephosphonate, yield 3.4 g (65%). 
1H-NMR (CDCl3 ) ll 1.2-1.3 (t, 6H, 2xCH3 ), 3.1-3.2 (d, 2H, 
S--CH2 ), 4.0-4.2 (m, 4H, 2xCH2 ), 7.2-7.4 (m, SH, Ph). 
Diethyl phenylsulfonylmethanephosphonate was prepared 
by oxidation of diethyl phenylmercaptomethanephosphonate cal pains can therefore be applied in the treatment of the above 
disorders. 
4. Drug Delivery. 
45 with potassium permanganate, yield 55%. 1 H-NMR (CDCl3 ) 
ll 1.2-1.3 (t, 6H, 2xCH3 ), 3.7-3.8 (d, 2H, S02-CH2 ), 4.1-4.2 
(m, 4H, 2xCH2), 7.5-7.7 (m, 3H, Ph), 7.9-8.0 (d, 2H, Ph). MS 
m/z 293 (M+l). 
This disclosure also provides a pharmaceutical composi-
tion, which comprises a compound according to Formula I 
and a pharmaceutically accepted carrier, diluent or excipient. 
Accordingly, the compounds of Formula I may be used in the 50 
manufacture of a medicament. For therapeutic use, the pep-
tidyl ally! sulfones may be administered orally, topically, or 
parenterally. The term parenteral, as used, includes subcuta-
neous injection, intravenous, intramuscular, intrasternal 
injection, or infusion techniques. The therapeutically effec- 55 
tive amount, and thus the appropriate dosage depends prima-
rily on the specific formulation and on the object of the 
therapy or prophylaxis. The amount of the individual doses as 
well as the administration is best determined by individually 
assessing each case. 
Example 2 
2-( tert-Butoxycarbony !amino )-3-pheny lpropionalde-
hyde (Boc-Phe-H). 
General Procedure for the Mixed Anhydride Coupling. 
N-Methylmorpholine was added to Boe-AA-OH or Cbz-
AA-OH in CH2Cl2 at -15° C. followed by isobutyl chloro-
formate. N-Methylmorpholine was added to a cooled solution 
(-15° C.) of HCl.H-AA-VS-Ph or N,O dimethylhydroxy-
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for example, 
60 !amine hydrochloride in CH2 Cl2 . This solution was added to 
the Boe-AA-OH or Cbz-AA-OH mixture, which had been 
stirring at -15° C. The mixture was continued to stir at -15° 
C. for 30 minutes, then warmed to room temperature and as tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or granules, emulsions, hard or soft cap-
sules, syrups, or elixirs. Dosage levels of the order of0.2 mg 65 
to 140 mg per kilogram of body weight per day are useful in 
the treatment of the above-indicated conditions (10 mg to 7 
continued to stir over night. The amount of solvent was 
doubled, then washed with citric acid (10%, 3x), saturated 
NaHC03 (3x), andbrine(3x), andfinallydried(MgS04 ). The 
solvent was evaporated. 
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Boc-Phe-N(OCH3 )CH3 was prepared from Boc-Phe-OH 
and N,0-dimethylhydroxylamine hydrochloride using stan-
dard mixed anhydride coupling procedure, yield 93%. 
1H-NMR (CDC13 ) o 1.4 (s, 9H, Boe), 2.8-2.9 (m, lH, CH2-
Phe), 3.0-3.1 (m, lH, CH2-Phe), 3.2 (s, 3H, N--CH3 ), 3.6 (s, 5 
3H, O-CH3 ), 4.9 (m, lH, a-H), S.2 (b, lH, NH), 7.1-7.3 (m, 
SH, Ph). MS (FAW) m/z 309 (M+l, 30%), 2S3 (M-tBu+l, 
100%). Reduction of Boc-Phe-N(OCH3)CH3 with lithium 
aluminum hydride according to a previously described 
methodgaveBoc-Phe-H,yield88%. 1H-NMR(CDCl3 )o 1.4 10 
(s, 9H, Boe), 3.1 (d, 2H, CH2-Phe), 4.4 (m, lH, a-H), S.O (b, 
lH, NH), 7.1-7.3 (m, SH, Ph), 9.6 (s, lH, CHO). MS (FAW) 
m/z 2SO (M+l, IS%), ISO (M-Boc+l, 100%). 
26 
VS-Ph.HCl using standard mixed anhydride coupling 
method, yield 81 %. 1H-NMR (CDC13 ) o 0.8-0.9 (2d, 6H, 
2xLeu-CH3 ), 1.4-1.6 (m, 2H, Leu-CH2), 2.06 (m, lH, Leu-
CH), 2.9-3.0(m, 2H, CH2-Phe), 3.9-4.0 (m, lH, a-H), 4.8-4.9 
(b, lH, a-H), 4.9-S.O (m, lH, NH), S.l (m, 2H, Cbz), 6.3-6.4 
(d & b, 2H, NH and CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.4 
(m, !OH, 2xPh), 7.S-7.7 (m, SH, S02-Ph). MS (ESI) m/z S3S. 
Example4C 
Phenyl-(3S )-3-(N-carbobenzy loxyvaly l)amino-4-pheny l-
but-1-eny l Sulfone (Cbz-Val-Phe-VS-Ph). Cbz-Val-Phe-VS-
Ph was prepared from Cbz-Val-OH and Phe-VS-Ph.HCl 
Example3A 15 using standard mixed anhydride coupling method, yield 98%. 
1H-NMR (CDC13 ) o 0.70-0.84 (2d, 6H, Val-CH3 ), 2.06 (m, 
lH, Val-CH), 2.91 (m, 2H, CH2-Phe), 3.82 (m, lH, a-H), 
4.80-4.90 (m, lH, a-H), S.10 (s, 2H, Cbz), S.96 (d, lH, NH) 
6.34 (d, lH, CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.4 (m, !OH, 
Phenyl-(3S)-3-amino-4-phenylbut-l-enyl Sulfone Hydro-
chloride (Phe-VS-Ph.HCl). Boc-Phe-VS-Ph was prepared by 
reaction ofBoc-Phe-H with diethyl phenylsulfonylmethane-
phosphonate in the presence of 2 N sodium methoxide, yield 
8S%. 1H-NMR (CDC13 ) o 1.3-1.4 (s, 9H, Boe), 2.9 (d, 2H, 
CH2-Phe), 4.4-4.S (b, lH, a-H), 4.6-4.7 (b, lH, NH), 6.3 (d, 
lH, CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.3 (m, SH, Ph), 
7.S-7.8 (m, SH, S02-Ph). MS (FAB+) m/z 388 (M+l, IS%), 
288 (M-Boc+ 1, 100% ). Boc-Phe-VS-Ph was deb locked with 25 
6.7 N HCl in EtOAc to give Phe-VS-Ph.HCl, yield 88%. 
1H-NMR (DMSO-d6 ) o 2.9-3.0 (m, lH, CH2-Phe), 3.1-3.2 
(m, lH, CH2-Phe), 4.2 (b, lH, a-H), 6.7-6.8 (m, 2H, CH=), 
7.1-7.3 (m, 6H, CH= and Ph), 7.6-7.8 (m, SH, S02-Ph), 
8.6-8.8 (b, 2H, NH2). MS (FAW) m/z 288 (M-Cl, 100%). 
Example3B 
20 2xPh), 7.S-7.7 (m, SH, S02-Ph). MS (ESI) m/z S2l (M+l, 
100%). 
Example4D 
Phenyl-(3S )-3-(N-carbobenzy loxyalany l)amino-4-phe-
ny lbut- l -enyl Sulfone (Cbz-Ala-Phe-VS-Ph). Cbz-Ala-Phe-
VS-Ph was prepared from Cbz-Ala-OH and Phe-VS-Ph.HCl 
using standard mixed anhydride coupling method, yield 88%. 
30 1H-NMR (CDC13 ) o l.2S (d, 3H, Ala-CH3 ), 2.91 (dq, 2H, 
CH2-Phe), 4.10 (m, lH, a-H), 4.80-4.90 (m, lH, a-H), S.10 
(s, 2H, Cbz), 6.34 (b, lH, NH), 6.39 (d, lH, CH=), 6.90-6.98 
(dd, lH, CH=), 7.10-7.39 (m, !OH, 2xPh), 7.SS (t, 2H, 
S02-Ph), 7.6S (t, lH, S02-Ph), 7.91 (d, 2H, S02-Ph). 13C Phenyl-(3R)-3-amino-4-phenylbut-l-enyl Sulfone Hydro-
chloride (D-Phe-VS-Ph.HCl). Boc-D-Phe-VS-Ph was pre-
pared by reaction ofBoc-D-Phe-H with diethyl phenylsulfo-
nylmethanephosphonate in the presence of 2 N sodium 
methoxide, yield 8S%. 1H-NMR (CDC13 ) o 1.3-1.4 (s, 9H, 
Boe), 2.9 (d, 2H, CH2-Phe), 4.4-4.S (b, lH, a-H), 4.6-4.7 (b, 
lH, NH), 6.3 (d, lH, CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.3 40 
(m, SH, Ph), 7.S-7.8 (m, SH, S02-Ph). MS (FAB+) m/z 388 
(M+l, 1S%),288(M-Boc+l, 100%).Boc-D-Phe-VS-Phwas 
deblocked with 6.7 N HCl in EtOAc to give D-Phe-VS-
Ph.HCl, yield 88%. 1H-NMR (DMSO-d6) o 2.9-3.0 (m, lH, 
CH2-Phe), 3.1-3.2 (m, lH), 4.2 (b, lH, a-H), 6.7-6.8 (m, 2H, 45 
CH=), 7.1-7.3 (m, 6H, CH= and Ph), 7.6-7.8 (m, SH, S02-
Ph), 8.6-8.8 (b, 2H, NH2). MS (FAW) m/z 288 (M-Cl, 
100%). 
35 NMR (400 MHz, CDC13 ) o 172.1, 1S6.3, 144.4, 140.8, 13S.7, 
134.2, 133.6, 131.2, 129.S, 129.4x3, 129.3, 128.8x2, 128.7, 
128.6, 128.4, 128.3, 127.8, 127.3, 126.9, 67.6, Sl.7, Sl.6, 
40.2, 19.4. 
Example SA 
Phenyl-3-(N-carbobenzy loxyleucy l)amino-4-pheny lbut-
2-eny l Sulfone (Cbz-Leu-Phe-AS-Ph). Butyllithium (3.63 
ml, 6.17 mmol, 1.7 M in pentane) was added dropwise to a 
solution oftert-butylhydroperoxide (2.SS ml, 8.42 mmol, 3.3 
Min toluene) in freshly distilled THF (80 ml) at - 78° C. under 
argon. A solution of Cbz-Leu-Phe-VS-Ph (3.00 g, S.61 
mmol) in dry THF (30 ml) was added dropwise. The reaction 
Example4A 
Phenyl-(3 S)-3-(N-carbobenzy loxyleucy l)amino-4-phe-
ny lbut- l -eny l Sulfone (Cbz-Leu-Phe-VS-Ph). Cbz-Leu-Phe-
VS-Ph was prepared from Cbz-Leu-OH and Phe-VS-Ph.HCl 
using standard mixed anhydride coupling method, yield 82%. 
1H-NMR (CDC13 ) o 0.8-0.9 (2d, 6H, 2xLeu-CH3 ), 1.4-1.6 
(m, 2H, Leu-CH2), 2.06 (m, lH, Leu-CH), 2.9-3.0 (m, 2H, 
CH2-Phe), 3.9-4.0 (m, lH, a-H), 4.8-4.9 (b, lH, NH), 4.9-S.O 
(m, lH, a-H), S.l (m, 2H, Cbz) 6.3-6.4 (d & b, 2H, NH and 
CH=), 6.9-7.0 (dd, lH, CH=), 7.1-7.4 (m, !OH, 2xPh), 
7.S-7.7 (m, SH, S02-Ph). MS (ESI) m/z S3S. 
Example4B 
Phenyl-(3R)-3-(N-carbobenzyloxyleucyl)amino-4-phe-
nylbut-l-enyl Sulfone (Cbz-Leu-D-Phe-VS-Ph). Cbz-Leu-
D-Phe-VS-Ph was prepared from Cbz-Leu-OH and D-Phe-
50 was continued to stir at -20° C. for 4S minutes (TLC Hex/ 
EtOAc 1 : 1). The reaction was quenched with saturated aque-
ous ammonium chloride (SO ml) and allowed to warm to room 
temperature. The organic layer was separated, and the aque-
ous layer was extracted with ethyl acetate (3x30 ml). The 
55 
extracts were then washed with aqueous sodium sulfite (10%, 
3x20 ml). The combined organic layers were dried (MgS04 ) 
and evaporated to give Cbz-Leu-Phe-AS-Ph as a white pow-
der, yield 63%. 1H-NMR (CDC13 ) o 0.8-0.9 (2d, 6H, 2xLeu-
60 CH3 ), 1.4-1.6 (m, 2H, Leu-CH2), 3.8 (s, 2H, CH2-Phe), 3.9 (d, 
2H, CH2-S02), 4.1 (m, lH, a-H), 4.8 (t, lH, CH=), 4.9-S.O 
(b, lH, NH), S.l (m, 2H, Cbz), 7.1-7.4 (m, !OH, 2xPh), 
7.S-7.7 (m, SH, S02-Ph), 8.4 (b, lH, NH). 13C NMR (400 
MHz, CDC13 )o 172.1, 1S6.3, 144.4, 140.8, 13S.7, 134.2, 
65 133.6, 131.2, 129.S, 129.4x2, 129.3, 128.8x2, 128.7, 128.6, 
128.4, 128.3, 127.8, 127.3, 126.9, 106.3, 67.6, S6.0, SS.6, 
41.7, 40.4, 22.1, 21.0, 18.4. MS (FAB+) m/z S3S (M+l, 
US 7,521,427 B2 
27 
100%).Anal. Calcd. forC30H34N20 5 S: C, 67.39; H, 6.S6; N, 
S.43. Found: C, 67.41; H, 6.S6; N, S.43. 
Example SB 
Phenyl-3-(N-carbo benzy loxyleucy l)amino-4-pheny lbut-
2-eny l Sulfone (Cbz-Leu-Phe-AS-Ph) (Isomer B). Cbz-Leu-
D-Phe-VS-Ph was treated with butyllithium and tert-butyl-
hydroperoxide in freshly distilled THF as described with 
Cbz-Leu-Phe-VS-Ph above to give Cbz-Leu-Phe-AS-Ph 10 
(Isomer B) as a white powder, yield 1S%. 1H-NMR (CDCl3) 
ll 0.8-0.9 (2d, 6H, 2xLeu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 
2.06 (m, lH, Leu-CH), 3.8 (s, 2H, CH2-Phe), 3.9 (d, 2H, 
CH2-S02), 4.1 (m, lH, a-H), 4.8 (t, lH, CH=), 4.9-S.O (b, 
lH, NH), S.l (m, 2H, Cbz), 7.1-7.4 (m, lOH, 2xPh), 7.S-7.7 15 
(m, SH, S02-Ph); 8.4 (b, lH, NH). MS (ESI) m/z S3S (M+l, 
100%).Anal. calcd. forC30H34N20 5 S: C, 67.39; H, 6.S6; N, 
S.43. Found: C, 67.12; H, 6.61; N, S.33. 
Example SC 20 
Phenyl-3-(N-carbo benzy loxyvaly l)amino-4-pheny lbut-2-
eny l Sulfone (Cbz-Val-Phe-AS-Ph). Cbz-Val-Phe-VS-Ph 
was treated with butyllithium and tert-butylhydroperoxide in 
freshly distilled THF as described with Cbz-Leu-Phe-VS-Ph 25 
above to give Cbz-Val-Phe-AS-Ph as a white powder, yield 
21%. 1H-NMR (CDCl3) ll 0.70-0.8S (2d, 6H, Val-CH3), 2.1 
(m, lH, Val-CH), 3.80 (d, 2H, CH2-Phe), 3.9S (m, 3H, CH2-
S02anda-H), 4.90 (t, lH, CH=), S.12 (m, 3H, NHandCbz), 
7.1-7.4 (m, lOH, 2xPh), 7.SS (t, 2H, S02-Ph), 7.6S (t, lH, 30 
S02-Ph), 7.91 (d, 2H, S02-Ph), 8.42 (b, lH, NH). 13C NMR 
(300 MHz, CDCl3) ll 172.1, 1S6.3, 144.4, 140.8, 13S.7, 
134.2, 133.6, 131.2, 129.S, 129.4x2, 129.3, 128.8x2, 128.7, 
128.6, 128.4, 128.3, 127.8, 127.3, 126.9, 106.3, 67.6, S6.0, 
SS.6, 41.7, 22.0, 21.0, 18.4. MS (FAW) m/z S2l (M+l, 35 
100%). Anal. calcd. for C29H32N20 5 S.1/10 H20: C, 66.67; 
H, 6.21; N, S.36. Found: C, 66.31; H, 6.23; N, S.26. 
Example SD 
40 
Phenyl-3-(N-carbo benzy loxyalany l)amino-4-pheny lbut-
2-eny l Sulfone (Cbz-Ala-Phe-AS-Ph). Cbz-Ala-Phe-VS-Ph 
was treated with butyllithium and tert-butylhydroperoxide in 
freshly distilled THF, as described with Cbz-Leu-Phe-VS-Ph 
above, to give Cbz-Ala-Phe-AS-Ph as a white powder, yield 45 
93%. 1H-NMR (CDCl3) ll 1.21 (d, 3H, Ala-CH3), 3.80 (m, 
4H, CH2-Phe andCH2-S02), 4.12 (q, lH, a-H), 4.88 (t, lH, 
CH=), S.ll (m, 3H, NHandCbz), 7.30(m, lOH, 2xPh), 7.SO 
28 
tions, which are cited herein comprise the state of the art and 
are incorporated herein by reference. 
What is claimed is: 
1. A compound of the formula: 
wherein, 
R1 is selected from the group consisting of phenyl-0-
CO- and phenyl-O--CO-AA1; 
AA1, is an aliphatic amino acid with the L configuration, D 
configuration, or no chirality at the alpha-carbon, 
wherein AA1 is selected from the group consisting of 
alanine, valine, leucine, isoleucine, norleucine, and nor-
valine, 
R2 is C1_10 alkyl substituted with phenyl; 
R3 is selected independently from the group consisting of 
phenyl, phenyl monosubstituted with K, phenyl disub-
stituted with K, phenyl trisubstituted with K, C1_10 alkyl 
with a phenyl group attached to the cl-10 alkyl, cl-10 
alkyl with an attached phenyl group monosubstituted 
with K, C1_10 alkyl with an attached phenyl group dis-
ubstituted with K, C1_10 alkyl with an attached phenyl 
group trisubstituted with K, 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02. 
CN, OH, C02H, CONH2. amino, C1_10 alkylamino, 
C2_12 dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, 
and C1_10 alkyl-S-; 
or a pharmaceutically acceptable salt, hydrate or solvate 
thereof. 
2. The compound of claim 1, wherein the double bond 
carbons have stereochemistry selected from the group con-
sisting of cis, trans, E, and Z. 
3. The compound of claim 1, wherein: 
AA1 is selected from the group consisting of alanine, 
valine, and leucine; 
R2 is C1 alkyl substituted with phenyl; and 
R3 is phenyl. 
4. The compound of claim 1, wherein: 
R1 is phenyl-0-CO-; 
R2 is C1 alkyl substituted with phenyl; and 
R3 is phenyl. (t, 2H, S02-Ph), 7.64 (t, lH, S02-Ph), 7.83 (d, 2H, S02-Ph), 
8.40 (b, lH, NH). 13C NMR (400 MHz, CDCl3) ll 172.1, 
lS6.3, 144.4, 140.8, 13S.7, 134.2, 133.6, 131.2, 129.S, 129.4x 
5. The compound of claim 1, wherein the compound is 
50 selected from the group consisting of Cbz-Ala-Phe-AS-Ph, 
Cbz-Val-Phe-AS-Ph, and Cbz-Leu-Phe-AS-Ph, wherein AS 
is an ally! sulfone. 2, 129.3, 128.8x2, 128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 
126.9, 107.2, 67.6, Sl.7, Sl.6, 40.2, 19.4. MS (FAB+) m/z 493 
(M+l, 100%). HRMS calcd. for C27H29N20 5 S: 493.17972. 
Obsd. 493.17663. Anal. calcd. for C27H28N20 5 S: C, 6S.83; 55 
H, S.73; N, S.69. Found: C, 6S.73; H, S.82; N, S.68. 
The above specification and Examples fully disclose how 
to make and use the compounds of the present disclosure. 
However, the present disclosure is not limited to the particular 
embodiments described hereinabove, but includes all modi-
fications thereof within the scope of the following claims. The 
various references to journals, patents, and other publica-
6. The compound of claim 1, wherein the compound is 
Cbz-Phe-AS-Ph, wherein AS is an ally! sulfone. 
7. The compound of claim 1, wherein said compound spe-
cifically inhibits cysteine proteases. 
8. A pharmaceutical composition comprising an effective 
amount of a compound of claim 1. 
9. The pharmaceutical composition of claim 8, further 
60 comprising a pharmaceutically acceptable carrier. 
* * * * * 
